Form 4: Pediatrix Director John Starcher Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director John M. Starcher Jr. was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.
Summary
- Director John M. Starcher Jr. acquired 7,196 shares of common stock in Pediatrix Medical Group, Inc. (MD).
- The shares were granted as restricted stock under the company's Amended and Restated 2008 Incentive Compensation Plan.
- The transaction occurred on May 7, 2026, at a price of $0 per share, representing an equity compensation award.
- Following this transaction, the director's total beneficial ownership increased to 73,260 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standard annual equity grant process indicates routine corporate governance.
Negatives
- None identified.
Risks
- Market volatility affecting the value of equity holdings.
- Regulatory compliance risks associated with Section 16 reporting requirements.
Future Outlook
The restricted shares are scheduled to vest on May 7, 2027, subject to the terms of the 2008 Incentive Compensation Plan.
Industry Context
StockSavvy.ai notes that annual equity grants to board members are a standard industry practice to ensure long-term alignment between leadership and shareholder interests in the healthcare services sector.
Comparison to Industry Standards
- The grant of restricted stock units (RSUs) as part of annual director compensation is consistent with standard corporate governance practices for publicly traded companies in the U.S.
- The reporting of this transaction via Form 4 complies with SEC Section 16(a) requirements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Mary Ann E. Moore and Tara McManus as attorneys-in-fact for SEC filings. | 2025-10-28 | Ensures efficient and compliant handling of future regulatory filings. |
Stakeholder Impact
- Shareholders: Increased alignment of director incentives with company performance.
Next Steps
- Vesting of the 7,196 restricted shares on May 7, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-10-28 | Date of Power of Attorney execution. |
| 2026-05-07 | Date of transaction and grant of restricted shares. |
| 2027-05-07 | Vesting date for the granted restricted shares. |
Keywords
Pediatrix Medical Group, MD, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.